Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-1 alpha (IL-1α), human recombinant is a proinflammatory cytokine produced by monocytes, macrophages, and dendritic cells. It plays a key role in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses. IL-1α signals through two receptors—IL-1RI and IL-1RII—shared with IL-1β. Its activity can be moderated by the naturally occurring antagonist protein IL-RA. The cytokine is involved in various immune responses, inflammatory processes (including sterile inflammation at sites of injury), hematopoiesis (blood cell formation), apoptosis induction following cell injury or necrosis. High levels of IL-1α are associated with chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-1 alpha, human recombinant.